BACKGROUND: Stents are essential tools in the management of pulmonary arterial (PA) stenosis in patients with congenital heart disease. Although stents can usually be reexpanded as children grow, resistant in-stent or peri-stent obstruction can complicate the management of PA stents. Angioplasty with ultra-high-pressure (UHP) balloons may facilitate successful treatment of stent-associated PA stenoses that are resistant to high-pressure dilation. METHODS AND RESULTS: We reviewed patients who underwent UHP angioplasty of in-stent or peri-stent PA stenoses that were resistant to high-pressure redilation. A resistant stenosis was defined as a residual balloon waist during high-pressure redilation of the stent, along with a pressure gradient and/or angiographic stenosis. Thirty-four lesions in 29 patients, including 8 with multiple concentric, overlapping, or adjacent stents, were included. The median age at UHP angioplasty was 9 years, and a median of 4 years had elapsed since unsuccessful high-pressure angioplasty. Thirty-one of the 34 (91% [81% to 100%]) UHP angioplasty procedures were successful in relieving the resistant stenosis. Balloon:waist diameter ratios were conservative (median 1.26), reflecting the ability of UHP balloons to "fracture" nearly all obstructions. After UHP dilation, lesion diameter increased by a median of 3.1 mm (36%), significantly more than after previous high-pressure dilation (1.3 mm, 19%; P<0.001). In 5 lesions, UHP angioplasty fractured the stent, allowing further vessel expansion. There were no vascular or other complications. CONCLUSIONS: UHP angioplasty was safe and effective for treatment of stent-related resistant PA stenosis in this series; the ability to fracture maximally expanded stents may extend the utility of stents in the pediatric population.
BACKGROUND: Stents are essential tools in the management of pulmonary arterial (PA) stenosis in patients with congenital heart disease. Although stents can usually be reexpanded as children grow, resistant in-stent or peri-stent obstruction can complicate the management of PA stents. Angioplasty with ultra-high-pressure (UHP) balloons may facilitate successful treatment of stent-associated PA stenoses that are resistant to high-pressure dilation. METHODS AND RESULTS: We reviewed patients who underwent UHP angioplasty of in-stent or peri-stent PA stenoses that were resistant to high-pressure redilation. A resistant stenosis was defined as a residual balloon waist during high-pressure redilation of the stent, along with a pressure gradient and/or angiographic stenosis. Thirty-four lesions in 29 patients, including 8 with multiple concentric, overlapping, or adjacent stents, were included. The median age at UHP angioplasty was 9 years, and a median of 4 years had elapsed since unsuccessful high-pressure angioplasty. Thirty-one of the 34 (91% [81% to 100%]) UHP angioplasty procedures were successful in relieving the resistant stenosis. Balloon:waist diameter ratios were conservative (median 1.26), reflecting the ability of UHP balloons to "fracture" nearly all obstructions. After UHP dilation, lesion diameter increased by a median of 3.1 mm (36%), significantly more than after previous high-pressure dilation (1.3 mm, 19%; P<0.001). In 5 lesions, UHP angioplasty fractured the stent, allowing further vessel expansion. There were no vascular or other complications. CONCLUSIONS: UHP angioplasty was safe and effective for treatment of stent-related resistant PA stenosis in this series; the ability to fracture maximally expanded stents may extend the utility of stents in the pediatric population.
Authors: Lynn F Peng; Doff B McElhinney; Alan W Nugent; Andrew J Powell; Audrey C Marshall; Emile A Bacha; James E Lock Journal: Circulation Date: 2006-05-30 Impact factor: 29.690
Authors: Colin J McMahon; Howaida G El Said; Julie A Vincent; Ronald G Grifka; Michael R Nihill; Frank F Ing; J Kennard Fraley; Charles E Mullins Journal: Cardiol Young Date: 2002-10 Impact factor: 1.093
Authors: Aphrodite Tzifa; Audrey C Marshall; Doff B McElhinney; James E Lock; Robert L Geggel Journal: J Am Coll Cardiol Date: 2007-02-16 Impact factor: 24.094
Authors: Athar M Qureshi; Doff B McElhinney; James E Lock; Michael J Landzberg; Peter Lang; Audrey C Marshall Journal: Cardiol Young Date: 2007-02-26 Impact factor: 1.093
Authors: Thomas J Forbes; Edwin Rodriguez-Cruz; Zahid Amin; Lee N Benson; Thomas E Fagan; William E Hellenbrand; Larry A Latson; Phillip Moore; Charles E Mullins; Julie A Vincent Journal: Catheter Cardiovasc Interv Date: 2003-07 Impact factor: 2.692
Authors: Brian A Boe; Jeffrey D Zampi; Kurt R Schumacher; Sunkyung Yu; Aimee K Armstrong Journal: Pediatr Cardiol Date: 2016-08-27 Impact factor: 1.655
Authors: Matthew A Crystal; Gareth J Morgan; Saar Danon; Robert G Gray; Daniel H Gruenstein; Brent M Gordon; Bryan H Goldstein Journal: Pediatr Cardiol Date: 2017-10-04 Impact factor: 1.655
Authors: Thomas Krasemann; Marco N Kruit; Arthur E van der Mark; Martijn Zeggelaar; Michiel Dalinghaus; Ingrid M van Beynum Journal: J Interv Cardiol Date: 2018-08-08 Impact factor: 2.279